KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Cash & Equivalents (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Cash & Equivalents data on record, last reported at $56.5 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 27.59% year-over-year to $56.5 million; the TTM value through Sep 2025 reached $56.5 million, down 27.59%, while the annual FY2023 figure was $179.9 million, 44.66% down from the prior year.
  • Cash & Equivalents reached $56.5 million in Q3 2025 per PACB's latest filing, up from $54.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $932.4 million in Q1 2021 and bottomed at $54.8 million in Q2 2025.
  • Average Cash & Equivalents over 5 years is $302.4 million, with a median of $310.4 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: soared 1254.01% in 2021, then crashed 79.78% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $460.7 million in 2021, then decreased by 29.44% to $325.1 million in 2022, then tumbled by 44.66% to $179.9 million in 2023, then tumbled by 56.66% to $78.0 million in 2024, then fell by 27.59% to $56.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $56.5 million in Q3 2025, $54.8 million in Q2 2025, and $78.0 million in Q3 2024.